NCT06353360 2024-08-09
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 2 Recruiting
Clinical Trials
4 trialsNCT05540275 2023-10-06
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting
NCT05811793 2023-04-13
Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.
Second Affiliated Hospital of Nanchang University
Phase NA Unknown
NCT05502991 2022-09-27
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting